Bacterial Infection Due to Helicobacter Pylori (H. Pylori) Clinical Trial
Official title:
Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated With H. Pylori Infection and Gastric Cancer Carcinogenesis
This is a research study for patients who currently have or previously had an H. pylori infection or who have gastric or esophageal cancer and who plan to undergo an endoscopy as part of their care. The purpose of this study is to find out how and why H. pylori infections can cause progression to gastric cancer and if it's possible for intervention prior to this progression.
H. pylori infection is a prevalent environmental cause of gastric cancer. The molecular mechanisms of carcinogenesis due to H. pylori remain unexplained and consequences of infection are variable and unpredictable. The aim of this research is to examine the RNA transcriptome of gastric cancer mucosa (gastric mucosa is the mucus membrane of the stomach), in patients with H. pylori infection and examine the spectrum of disease associated with infection. We will also examine bacterial content of samples to pinpoint the specific H. pylori strain(s) and the stomach microbial profile to correlate with the gastric mucosal transcriptome and predisposition of gastric cancer. Patients with prior or current active H. pylori infection who are planning to under endoscopic evaluation will be eligible for participation. From these patients, we plan to take up to four additional biopsies from each area of stomach already being sampled. The biopsies will be used for next-generation RNA and DNA sequencing and novel bioinformatics analyses. The analysis will be performed at Weill Cornell Medical College by Doron Betel, PhD. The sequencing will be performed in the Epigenetics Core laboratory under the supervision of Doron Betel, who will be working closely with the principal investigator, Manish A. Shah, M.D. Examination of the genetic impact of H. pylori infection in patients may expose genetic factors that influence gastric cancer carcinogenesis and give deeper insight into molecular pathways that serve as candidate biomarkers for gastric cancer carcinogenesis. Our goal is to distinguish patients with chronic H. pylori infection who are at risk of subsequently developing gastric cancer from the vast majority of patients with H. pylori infection who do not develop malignancy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02553083 -
High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT01897909 -
The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana
|
||
| Completed |
NCT02160860 -
Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
|
N/A | |
| Completed |
NCT03367897 -
Bleeding Ulcer and Erosions Study "BLUE Study"
|
||
| Completed |
NCT01506986 -
Helicobacter Eradication Aspirin Trial
|
Phase 4 | |
| Recruiting |
NCT01572597 -
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
|
Phase 4 | |
| Completed |
NCT01623154 -
POCone-UBiT-IR300 Pediatric Comparison Study
|
Phase 4 | |
| Completed |
NCT01591486 -
Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding
|
N/A | |
| Completed |
NCT03124199 -
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
|
Phase 3 | |
| Recruiting |
NCT02674802 -
Reinfection After Eradication of Helicobacter Pylori Infection
|
N/A | |
| Completed |
NCT02092506 -
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
|
Phase 4 | |
| Completed |
NCT01902589 -
Resistance of Helicobacter Pylori to Antibiotics in Children
|
N/A |